Riskpilot← Back to searchSign inGet full accessRita Pharma Oy
OYDissolvedY-tunnus 2419227-0Fabianinkatu 25-B5Security and commodity contracts brokerage · NACE 6612Est. 2011— employees
Revenue 2024
EUR 0
EBITDA margin
—
-17% vs 2023
Equity ratio
99.6%
Financial strength
Net profit 2024
EUR 4K
-75% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR 14K | -17% |
| Net profit | EUR 4K | -75% |
| Total assets | EUR 747K | +0% |
| Equity | EUR 744K | +1% |
| Employees | — | — |
Legal name
Rita Pharma Oy
Y-tunnus number
2419227-0
Legal form
Osakeyhtiö
NACE code
6612 · Security and commodity contracts brokerage
Founded
19. heinäkuuta 2011
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
kiinteistöjen ja maa-alueiden, osuuksien, osakkeiden ja muiden arvopaperien ostaminen, hallitseminen ja myyminen.
Address
Fabianinkatu 25-B5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26 | 0 |
| Staff expenses | — | — | — | −0 | −0 |
| EBITDA | 12 | 14 | 17 | 17 | 14 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 12 | 14 | 17 | 17 | 14 |
| Net financials | −39 | 183 | 111 | 3 | −7 |
| Profit before tax | −27 | 197 | 128 | 20 | 7 |
| Tax | 5 | 32 | 29 | 3 | 3 |
| Net profit | −32 | 165 | 99 | 17 | 4 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 189 | 1 216 | 823 | 744 | 747 |
| Equity | 1 111 | 1 186 | 795 | 740 | 744 |
| Long-term debt | 25 | — | — | 0 | 0 |
| Short-term debt | 54 | 30 | 28 | 4 | 3 |
| Total debt | 79 | 30 | 28 | 4 | 3 |
EBITDA margin
1411300.0%
This company
15.8%
Market median
+8932178% vs market
20202024
Equity ratio
99.6%
This company
38.2%
Market median
+161% vs market
20202024
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20202024
Net profit margin
422500.0%
This company
8.1%
Market median
+5215949% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JI Deputy Member | Deputy Member | 2024 |
| Former (1) | ||
PJ | Audit | 2011 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairperson | 2024 | |
| Former (1) | ||
| Board of Directors | 2011 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Rita Pharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pekka Johannes Neuvonen | Audit | 0 companies |
| Juho Ilmari Koskenkorva | Deputy Member | 0 companies |
| Marja Elina Ritala | Board of Directors | 0 companies |
| Susanna Maarit Ritala | Board of Directors | 0 companies |
| Frans Juho Hermanni Ritala | Chairperson | 0 companies |